𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib

✍ Scribed by E. Chorianopoulos; D. Jäger*; H. A. Katus; N. Frey

Publisher
Springer
Year
2007
Tongue
English
Weight
154 KB
Volume
96
Category
Article
ISSN
1861-0684

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Targeted molecular therapy of head and n
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model
✍ Daisuke Sano; David R. Fooshee; Mei Zhao; Genevieve A. Andrews; Mitchell J. Fred 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 367 KB 👁 2 views

## Abstract ## Background We investigated the effects of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR‐2) and epidermal growth factor receptor (EGFR), alone and in combination with paclitaxel in an orthotopic mouse model of human head and neck squamous cell carci

A population-based study evaluating the
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer
✍ Daniel Y. C. Heng; Kim N Chi; Nevin Murray; Tao Jin; Jorge A Garcia; Ronald M Bu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 1 views

## Abstract ## BACKGROUND: Sunitinib has replaced interferon (IFN) as a first‐line standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. ## METH